Mechanical thrombectomy for acute ischemic stroke
Ask the expert
Report presents summary of reimbursement situation for mechanical thrombectomy for acute ischemic stroke in European countries. Day case admissions are not considered in the report.
Report includes essential information about reimbursement and national funding, including:
- Brief overview of reimbursement system for medical devices
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions in indications or scenarios for use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- Austria
- Belgium
- Denmark
- England (UK)
- France
- Germany
- Italy
- Netherlands
- Norway
- Sweden
- Switzerland
It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.
Manufacturers of devices for mechanical thrombectomy for acute ischemic stroke include:
- Acandis (APERIO)
- Amnis Therapeutics (GOLDEN RETRIEVER)
- Anaconda Brain (Anaconda Biomed)
- Balt Extrusion (CATCH)
- DePuy Synthes (REVIVE SE)
- Medtronic (Solitaire; MindFrame Capture)
- Microvention (SOFIA PLUS, RIC)
- Penumbra (Penumbra System, Reperfusion Catheters ACE, Reperfusion Catheters MAX, 3D Revascularization Device, Pump MAX, Velocity)
- Phenox (pRESET, pRESET LITE)
- Rapid Medical (TIGERTRIEVER)
- Stryker (Trevo XP Thrombectomy catheter)
Table of content
1. Introduction and summary
2. Contents
3. Executive summary table
4. Methodology
5. Reimbursement analysis in Austria
5.1. Overview of the reimbursement system
5.2. Reimbursement for mechanical thrombectomy in acute ischemic stroke
5.2.1. Procedure coding
5.2.2. Diagnosis coding
5.2.3. Payment mechanism and reimbursement tariffs
5.2.4. Policy considerations
5.2.4.1. Health technology assessments by LBI-HTA
6. Reimbursement analysis in Belgium
6.1. Overview of the reimbursement system
6.2. Reimbursement for mechanical thrombectomy in acute ischemic stroke
6.2.1. Procedure coding
6.2.2. Diagnosis coding
6.2.3. Payment mechanism and reimbursement tariffs
6.2.4. Policy considerations
7. Reimbursement analysis in Denmark
7.1. Overview of the reimbursement system
7.2. Reimbursement for mechanical thrombectomy in acute ischemic stroke
7.2.1. Procedure coding
7.2.2. Diagnosis coding
7.2.3. Payment mechanism and reimbursement tariffs
8. Reimbursement analysis in England
8.1. Overview of the reimbursement system
8.2. Reimbursement for mechanical thrombectomy in acute ischemic stroke
8.2.1. Procedure coding
8.2.2. Diagnosis coding
8.2.3. Payment mechanism and reimbursement tariffs
8.2.4. Policy considerations
8.2.4.1. Specifics of commissioning of the procedure
8.2.4.2. Health technology assessments by NICE
9. Reimbursement analysis in France
9.1. Overview of the reimbursement system
9.2. Reimbursement for mechanical thrombectomy in acute ischemic stroke
9.2.1. Procedure coding
9.2.2. Diagnosis coding
9.2.3. Payment mechanism and reimbursement tariffs
9.2.4. Policy considerations by HAS
10. Reimbursement analysis in Germany
10.1. Overview of the reimbursement system
10.2. Reimbursement for mechanical thrombectomy in acute ischemic stroke
10.2.1. Procedure coding
10.2.2. Diagnosis coding
10.2.3. Payment mechanism and reimbursement tariffs
10.2.4. Policy considerations
11. Reimbursement analysis in Italy
11.1. Overview of the reimbursement system
11.2. Reimbursement for mechanical thrombectomy in acute ischemic stroke
11.2.1. Procedure coding
11.2.2. Diagnosis coding
11.2.3. Payment mechanism and reimbursement tariffs at national level
11.2.4. Payment mechanism and reimbursement tariffs at regional level
12. Reimbursement analysis in the Netherlands
12.1. Overview of the reimbursement system
12.2. Reimbursement for mechanical thrombectomy in acute ischemic stroke
12.2.1. Procedure coding
12.2.2. Diagnosis coding
12.2.3. Payment mechanism and reimbursement tariffs
12.2.4. Policy considerations by Dutch Healthcare Institute (CIN)
13. Reimbursement analysis in Norway
13.1. Overview of the reimbursement system
13.2. Reimbursement for mechanical thrombectomy in acute ischemic stroke
13.2.1. Procedure coding
13.2.2. Diagnosis coding
13.2.3. Payment mechanism and reimbursement tariffs
13.2.4. Policy considerations
14. Reimbursement analysis in Sweden
14.1. Overview of the reimbursement system
14.2. Reimbursement for mechanical thrombectomy in acute ischemic stroke
14.2.1. Procedure coding
14.2.2. Diagnosis coding
14.2.3. Payment mechanism and reimbursement tariffs
14.2.4. Policy considerations
15. Reimbursement analysis in Switzerland
15.1. Overview of the reimbursement system
15.2. Reimbursement for mechanical thrombectomy in acute ischemic stroke
15.2.1. Procedure coding
15.2.2. Diagnosis coding
15.2.3. Payment mechanism and reimbursement tariffs
15.2.4. Policy considerations
16. Disclaimer
24
Jul 2020
In February 2020, the Office for Health Technology Assessment (HTA) of Basque Country OSTEBA published an HTA report for efficacy and safety of mechanical thrombectomy (MT) in the treatment of patients with ischaemic stroke beyond 6 hours after onset or with an unknown time of onset. According to the report, the use of MT, together with standard medical treatment (SMT) in such patients, is justified provided that they meet the neuroimaging selection criteria applied to the studies analyzed.
Read more14
Nov 2019
In early September 2019, the Innovation Committee of the Federal Joint Committee (G-BA) has published an overview of new research projects in the area of health services to be funded by the Innovation Fund in the future.
Read more06
Aug 2019
In June 2019, the National Institute for Health and Care Excellence (NICE) published six new interventional procedure guidance, one new Medical technologies guidance for Endocuff Vision for assisting visualisation during colonoscopy, and two new MedTech innovation briefings (for Danis stent for acute oesophageal variceal bleeds, and The OPTIMIZER smart system for managing heart failure).
Read more27
Mar 2019
On the Interterritorial Council that took place March 4th, 2019, the Working Plan for the Spanish Network for Health Technology Assessment was agreed and published. The working plan includes 22 health technology assessment reports, 7 monitoring studies, 9 clinical practice guidelines, and 1 evidence-based product.
Read more01
Nov 2018
The French National Authority for Health (HAS) regularly publishes new decisions about add-on reimbursement for medical devices. The decisions made in the period July-September 2018 concern various types of devices. In total, 52 decisions were published.
Read more26
Sep 2018
In the second half of July, the National Institute for Health and Care Excellence (NICE) published five new Interventional Procedure Guidance for low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing, fresh fractures at high risk of non-healing, superior capsular augmentation for massive rotator cuff tears, transaxial interbody lumbosacral fusion for severe chronic low back pain and two new Medtech Innovation Briefings for remote ECG interpretation consultancy services for cardiovascular disease and mechanical thrombectomy devices for acute ischaemic stroke.
Read more18
Jan 2018
A 62-page reimbursement report covers mechanical thrombectomy for stroke. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland.
Read more20
Nov 2017
Annual report from the Italian Society of Interventional Cardiology (GISE) shows increasing trends in procedural volume of percutaneous coronary interventions (PCI), transcatheter aortic valve implantations (TAVI), mitral clip implantations, closure of left atrial appendage (LAA) and patent foramen ovale (PFO).
Read more28
Sep 2017
MTRC has analyzed timing of decision-making (negotiation about price, final ministerial decision and publication of the decision) after recommendation by CNEDiMTS about expected benefit (AS) and added clinical value (ASA) for invasive non-implantable medical devices reimbursed via LPPR list, title V. Since establishment of the title V program, 5 technologies were added to the List (stent retrievers for stroke; peripheral drug-coated balloons). Time from the recommendation by CNEDiMTS until the start of reimbursement varied from 7 to 13 months (9.4 months on average).
Read more21
Aug 2017
New material codes for neurovascular self-expanding stent retrievers for clot removal (mechanical thrombectomy for stroke) and foam preparation for hysterosalpingosonography were added to the List of reimbursable devices of the Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) in July.
Read more24
May 2017
The National Board (Socialstyrelsen) has developed a new national guideline for the treatment of stroke with a significant focus on mechanical thrombectomy. MTRC provides an overview of key recommendations, which concern diagnosis and treatment phase using medical technologies.
Read more08
May 2017
French National Authority for Health (HAS) has initiated an assessment of organizational impact of mechanical thrombectomy on the system of stroke management in France with objective to find the most adequate way of further introduction of the method into French health care system.
Read more02
May 2017
The Forum of Norwegian payers made decision about introduction of three medical technologies: mechanical thrombectomy for stroke, baroreflex activation therapy for resistant hypertension and non-invasive prenatal testing for detection of trisomy 13, 18 and 21.
Read more13
Apr 2017
The procedure will be included into Prescribed Specialized Services. About 8000 patients can benefit from the treatment annually. Other stroke treatments are commissioned by Clinical Commissioning Groups.
Read more